IMC-CS4

BIOLOGICAL2 trials

Sponsors

Eli Lilly and Company, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

NeoplasmsPancreatic Cancer

Early Phase 1

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

CompletedNCT03153410

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer

Start: 2018-09-27End: 2023-08-29Updated: 2025-01-09

Phase 1

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

CompletedNCT01346358

Eli Lilly and CompanyNeoplasms

Start: 2011-06-15End: 2018-05-31Updated: 2024-09-19

Related Papers

GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.

2021-08-0136 citations

LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.

2021-02-2332 citations

A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2017-05-207 citations